About MediciNova (NASDAQ:MNOV)
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500
Debt
Debt-to-Equity RatioN/A
Current Ratio9.83%
Quick Ratio9.83%
Price-To-Earnings
Trailing P/E Ratio-33.94
Forward P/E Ratio-29.47
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book10.47
Profitability
EPS (Most Recent Fiscal Year)($0.33)
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-32.09%
Return on Assets-28.09%
Miscellaneous
Employees9
Outstanding Shares40,930,000
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.
What price target have analysts set for MNOV?
1 brokerages have issued twelve-month target prices for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next year. View Analyst Ratings for MediciNova.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Flexion Therapeutics (FLXN), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Inflarx (IFRX), ARMO BioSciences (ARMO), Collegium Pharmaceutical (COLL), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Deciphera Pharmaceuticals (DCPH), Urogen Pharma (URGN), CymaBay Therapeutics (CBAY), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Karyopharm Therapeutics (KPTI) and NuCana (NCNA).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
- Mr. Ryan J. Selhorn, CFO & Principal Accounting Officer (Age 36)
- Mr. Masatsune Okajima, Head of Japanese Office and VP (Age 50)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
- Mr. Geoffrey G. O'Brien J.D., M.B.A., VP (Age 49)
Has MediciNova been receiving favorable news coverage?
Press coverage about MNOV stock has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MediciNova earned a news sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $11.20.
How big of a company is MediciNova?
MediciNova has a market capitalization of $473.13 million. The biopharmaceutical company earns $-11,160,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. MediciNova employs 9 workers across the globe.
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
MediciNova (NASDAQ:MNOV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for MediciNova in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 96.43%. The high price target for MNOV is $22.00 and the low price target for MNOV is $22.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.00 | N/A | N/A | N/A |
| Price Target Upside: | 96.43% upside | N/A | N/A | N/A |
MediciNova (NASDAQ:MNOV) Consensus Price Target History
MediciNova (NASDAQ:MNOV) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/28/2018 | B. Riley | Initiated Coverage | Buy | $22.00 | High |  |
| 4/18/2017 | Credit Suisse Group | Initiated Coverage | Outperform -> Outperform | | High | |
(Data available from 4/21/2016 forward)
MediciNova (NASDAQ:MNOV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MediciNova (NASDAQ MNOV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.20%
Institutional Ownership Percentage: 18.79%
MediciNova (NASDAQ MNOV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/21/2017 | Yoshio Ishizaka | Director | Buy | 5,000 | $5.17 | $25,850.00 | 5,000 | |
| 5/15/2017 | Yutaka Kobayashi | Director | Buy | 1,000 | $5.60 | $5,600.00 | 81,800 | |
| 5/12/2017 | Yutaka Kobayashi | Director | Buy | 24,000 | $5.62 | $134,880.00 | 81,800 | |
| 9/15/2016 | Yutaka Kobayashi | Director | Buy | 11,800 | $6.44 | $75,992.00 | 81,800 | |
| 9/9/2016 | Yutaka Kobayashi | Director | Buy | 10,000 | $6.67 | $66,700.00 | 70,000 | |
| 7/5/2016 | Geoffrey Obrien | VP | Sell | 3,300 | $8.00 | $26,400.00 | 8,300 | |
| 12/10/2014 | Yutaka Kobayashi | Director | Buy | 12,000 | $3.54 | $42,480.00 | | |
| 11/26/2014 | Yutaka Kobayashi | Director | Buy | 10,000 | $3.07 | $30,700.00 | | |
| 11/20/2014 | Yutaka Kobayashi | Director | Buy | 13,000 | $3.19 | $41,470.00 | | |
| 11/19/2014 | Yoshio Ishizaka | Director | Buy | 5,000 | $2.86 | $14,300.00 | | |
| 9/11/2014 | Yutaka Kobayashi | Director | Buy | 10,000 | $2.95 | $29,500.00 | | |
| 9/3/2014 | Yutaka Kobayashi | Director | Buy | 15,000 | $2.66 | $39,900.00 | | |
| 12/12/2013 | Tatsuo Izumi | Director | Sell | 71,270 | $2.10 | $149,667.00 | | |
| 11/18/2013 | Tatsuo Izumi | Director | Buy | 1,270 | $2.21 | $2,806.70 | | |
| 5/21/2013 | Arlene Morris | Director | Sell | 8,800 | $3.28 | $28,864.00 | | |
| 5/13/2013 | Tatsuo Izumi | Director | Buy | 158,730 | $3.15 | $499,999.50 | | |
(Data available from 1/1/2013 forward)
MediciNova (NASDAQ MNOV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | 3 Things In Biotech, April 16: Liver, Liver, And More Liver
seekingalpha.com - April 17 at 10:00 AM |
 | -$0.11 EPS Expected for MediciNova, Inc. (MNOV) This Quarter
www.americanbankingnews.com - April 16 at 3:12 PM |
| Zacks: MediciNova, Inc. (MNOV) Given $18.33 Average Target Price by Brokerages
www.americanbankingnews.com - April 15 at 3:11 AM |
 | Medicinova (MNOV) Announces Presentation of Positive Results from Interim Analysis of Phase 2 Trial of MN-001 in NASH / NAFLD
www.streetinsider.com - April 14 at 9:51 AM |
| MediciNova's tipelukast shows treatment effect in mid-stage NASH/NAFLD study; shares up 8% premarket
seekingalpha.com - April 13 at 10:08 AM |
| MediciNova's MN-166 Has Significant Potential In Progressive MS
seekingalpha.com - April 13 at 10:08 AM |
 | MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France
finance.yahoo.com - April 13 at 10:08 AM |
| Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results
seekingalpha.com - April 3 at 4:20 PM |
| MediciNova (MNOV) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 12:11 PM |
| Pre-Open Movers 04/02: (SLS) (MNOV) (CVLT) Higher; (ALKS) (SORL) (ITCI) Lower (more...)
www.streetinsider.com - April 2 at 4:19 PM |
 | Here's Why MediciNova Jumped as Much as 26.2% Today
www.msn.com - April 2 at 4:19 PM |
| Here's Why MediciNova Jumped as Much as 26.2% Today
finance.yahoo.com - April 2 at 4:19 PM |
 | MediciNova Announces Phase 2 Trial of MN-001 (...
www.benzinga.com - April 2 at 10:09 AM |
| MediciNova's MN-001 successful in mid-stage NASH study
seekingalpha.com - April 2 at 10:09 AM |
| Analysts Anticipate MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - March 30 at 7:10 PM |
| MediciNova Flunks Mid-Stage Study, But Not All Is Lost
seekingalpha.com - March 30 at 4:19 PM |
| MediciNova, Inc. Expected to Post Q1 2018 Earnings of ($0.10) Per Share (MNOV)
www.americanbankingnews.com - March 30 at 6:52 AM |
| MediciNova (MNOV) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 29 at 4:10 PM |
| Zacks: Brokerages Set $18.33 Target Price for MediciNova, Inc. (MNOV)
www.americanbankingnews.com - March 29 at 1:26 PM |
| MediciNova teams up with Australian cancer center to evaluate MN-166 in chemotherapy-induced peripheral neuropathy
seekingalpha.com - March 29 at 10:06 AM |
| Pre-Open Movers 03/29: (MOV) (MGEN) (PSDV) Higher; (ZSAN) (MNOV) (MCD) Lower (more...)
www.streetinsider.com - March 29 at 10:06 AM |
| B. Riley Initiates Coverage on MediciNova (MNOV)
www.americanbankingnews.com - March 28 at 8:06 AM |
| MediciNova (MNOV) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 1:58 PM |
| MediciNova (MNOV) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 11:29 AM |
| MediciNova (MNOV) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 25 at 9:51 AM |
| BidaskClub Lowers MediciNova (MNOV) to Buy
www.americanbankingnews.com - March 22 at 12:54 AM |
| Critical Review: MediciNova (MNOV) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - March 19 at 1:55 AM |
| Analysts Expect MediciNova, Inc. (MNOV) to Announce ($0.09) Earnings Per Share
www.americanbankingnews.com - March 13 at 9:26 PM |
| MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo
feeds.benzinga.com - March 12 at 8:34 PM |
| MediciNova (MNOV) & The Competition Financial Survey
www.americanbankingnews.com - March 11 at 9:48 AM |
| Brokerages Expect MediciNova, Inc. (MNOV) to Announce ($0.09) EPS
www.americanbankingnews.com - March 7 at 1:33 PM |
| MediciNova (MNOV) vs. Its Rivals Critical Survey
www.americanbankingnews.com - March 4 at 9:28 AM |
| Financial Comparison: MediciNova (MNOV) & The Competition
www.americanbankingnews.com - March 3 at 10:34 AM |
| Short Interest in MediciNova, Inc. (MNOV) Grows By 39.6%
www.americanbankingnews.com - March 3 at 3:26 AM |
| MediciNova to Present at the Cowen Health Care Conference in Boston
feeds.benzinga.com - February 25 at 6:51 PM |
| Analysts Expect MediciNova, Inc. (MNOV) to Announce -$0.09 EPS
www.americanbankingnews.com - February 24 at 5:12 PM |
| Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet?
finance.yahoo.com - February 22 at 9:28 AM |
| Zacks Investment Research Comments on MediciNova, Inc.'s Q1 2018 Earnings (MNOV)
www.americanbankingnews.com - February 19 at 2:04 AM |
| MNOV: Raises $40 Million in Underwritten Public Offering
finance.yahoo.com - February 16 at 4:26 PM |
| Critical Analysis: MediciNova (MNOV) vs. Its Peers
www.americanbankingnews.com - February 15 at 11:12 PM |
| MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study
finance.yahoo.com - February 9 at 9:04 AM |
| Here's Why MediciNova, Inc. Stock Is Sliding Today
finance.yahoo.com - February 8 at 4:31 PM |
 | Here's Why MediciNova, Inc. Stock Is Sliding Today
www.fool.com - February 8 at 1:42 PM |
| Medicinova (MNOV) Prices 4.42M Common Share Offering at $9.05/Sh
www.streetinsider.com - February 8 at 9:03 AM |
| Zacks: Brokerages Expect MediciNova, Inc. (MNOV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 8 at 1:18 AM |
 | ARRY's COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTD
www.nasdaq.com - February 7 at 9:03 AM |
 | Active-Investors: Blog Exposure - MediciNova's MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
www.finanznachrichten.de - February 5 at 8:59 AM |
| Blog Exposure - MediciNova’s MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial
finance.yahoo.com - February 5 at 8:59 AM |
| MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
finance.yahoo.com - January 31 at 9:12 AM |
| MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego
finance.yahoo.com - January 31 at 9:12 AM |
MediciNova (NASDAQ:MNOV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MediciNova (NASDAQ:MNOV) Income Statement, Balance Sheet and Cash Flow Statement
MediciNova (NASDAQ MNOV) Stock Chart for Saturday, April, 21, 2018
Loading chart…
